PMV Pharmaceuticals, Inc. 8-K

What Happened

• PMV Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2026. The company issued a press release on May 12, 2026 reporting its quarterly results; the full text of that press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference. The Form 8-K was signed by Michael Carulli, Chief Financial Officer.

Key Details

• Filing date: May 12, 2026 (Form 8-K filed reporting results of operations and financial condition, Item 2.02).
• Reporting period: Quarter ended March 31, 2026.
• Press release: Attached as Exhibit 99.1 and incorporated by reference in the 8-K.
• Signature: Report executed by Michael Carulli, Chief Financial Officer (Principal Financial and Accounting Officer).

Why It Matters

• This 8-K notifies investors that PMV has publicly released its quarterly earnings and financial condition information; the attached press release is the primary source for revenue, earnings, cash position, guidance, and other metrics investors monitor.
• Retail investors should review the Exhibit 99.1 press release (and the company’s subsequent 10-Q) to see the actual earnings, revenue, and any commentary on operations or outlook, because those figures can affect valuation and near-term trading.